Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long, Kyle Beckwith, Priscilla Do, Bethany L Mundy, Amber Gordon, Amy M Lehman, Kami J Maddocks, Carolyn Cheney, Jeffrey A Jones, Joseph M Flynn, Leslie A Andritsos, Farrukh Awan, Joseph A Fraietta, Carl H June, Marcela V Maus, Jennifer A Woyach, Michael A Caligiuri, Amy J Johnson, Natarajan Muthusamy, John C Byrd, Meixiao Long, Kyle Beckwith, Priscilla Do, Bethany L Mundy, Amber Gordon, Amy M Lehman, Kami J Maddocks, Carolyn Cheney, Jeffrey A Jones, Joseph M Flynn, Leslie A Andritsos, Farrukh Awan, Joseph A Fraietta, Carl H June, Marcela V Maus, Jennifer A Woyach, Michael A Caligiuri, Amy J Johnson, Natarajan Muthusamy, John C Byrd
Abstract
Background: Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies.
Methods: Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated.
Results: Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells.
Conclusions: Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers.
Trial registration: ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025.
Funding: The National Cancer Institute.
Conflict of interest statement
Conflict of interest: K.J. Maddocks received grants and nonfinancial support from Pharmacyclics, Merck, and Bristol-Myers Squibb (BMS), and personal fees from Pharmacyclics, BMS, and Janssen, outside the submitted work. J.A. Jones received personal fees and other support from Janssen, Pharmacyclics, and AbbVie, outside the submitted work. L.A. Andritsos received grants from Pharmacyclics during the conduct of the study. F. Awan received grants and personal fees from Pharmacyclics, personal fees from Gilead, and grants from Innate Pharma, outside the submitted work. J.A. Fraietta has a patent for the treatment of cancer using anti-CD19 chimeric antigen receptor licensed to the University of Pennsylvania. C.H. June received grants from Novartis during the conduct of the study and other support from Novartis and Tmunity Therapeutics, outside the submitted work. J.A. Woyach received research funding from Karyopharm Therapeutics, MorphoSys, AbbVie, and Acerta Pharma, outside the submitted work, and is on the advisory board for Janssen. A.J. Johnson has filed a patent on ibrutinib as immune-modulation agent. N. Muthusamy has filed a patent on ibrutinib as an immune-modulation agent. J.C. Byrd has filed a patent on ibrutinib as an immune-modulation agent.
Figures
Source: PubMed